Bibliography
- BELLACOSA A, KUMAR CC, DI CRISTOFANO A, TESTA JR: Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv. Cancer Res. (2005) 94:29-86.
- MITSIADES CS, MITSIADES N, KOUTSILIERIS M: The Akt pathway: molecular targets for anti-cancer drug development. Curr. Cancer Drug Targets (2004) 4(3):235-256.
- VIVANCO I, SAWYERS CL: The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nature Rev. (2002) 2:489-501.
- LI Q, ZHU G: Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer. Curr. Topics Med. Chem. (2002) 2(9):939-971.
- LUO Y, SMITH RA, GUAN R et al.: Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition. Biochemistry (2004) 43(5):1254-1263.
- ZHU GD, GONG J, GANDHI VB et al.: Design and synthesis of pyridine–pyrazololpyridine-based inhibitors of protein kinase B/Akt. Bioorg. Med. Chem. (2007) 15:2441-2452.
- LUO Y, SHOEMAKER AR, LIU X et al.: Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol. Cancer Ther. (2005) 4(6):977-986.
- REDAELLI C, GRANUCCI F, DE GIOIA L, CIPOLLA L: Synthesis and biological activity of Akt/PI3K inhibitors. Mini-Rev. Med. Chem. (2006) 6:1127-1136.
- BARNETT SF, BILODEAU MT, LINDSLEY CW: The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation. Curr. Topics Med. Chem. (2005) 5:109-125.
- QIAO L, NAN F, KUNKEL M, GALLEGOS A, POWIS G, KOZIKOWSKI AP: 3-Deoxy-D-myo- inositol 1-phosphate, 1-phosphonate, and ether lipid analogues as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth. J. Med. Chem. (1998) 41(18):3303-3306.
- HU Y, QIAO L, WANG S et al.: 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt and cancer cell growth. J. Med. Chem. (2000) 43(16):3045-3051.
- KOZIKOWSKI AP, SUN H, BROGNARD J, DENNIS PA: Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. J. Am. Chem. Soc. (2003) 125(5):1144-1145.
- LIPPA B: Phosphatidylinositol analogues that block the activation of Akt for the treatment of cancer. Expert Opin. Ther. Patents (2004) 14(9)1379-1383.
- MAKOSZA M, SIENKIEWICZ K: Hydroxylation of nitroarenes with alkyl hydroperoxide anions via vicarious nucleophilic substitution of hydrogen. J. Org. Chem. (1998) 63(13):4199-4208.
- KELLEY JL, KOBLE CS, DAVIS RG et al.: 1-(Fluorobenzyl)-4-amino-1H-1,2,3- triazolo[4,5-c]pyridines: synthesis and anticonvulsant activity. J. Med. Chem. (1995) 38(20):4131-4134.
Patents
- ABBOTT LABORATORIES: US030181366 (2003).
- MERCK AND CO., INC.: WO2002083064 (2002).
- MERCK AND CO., INC.: WO20040102360 (2004).
- MERCK AND CO., INC.: WO2006135627 (2006).
- PFIZER, INC.: WO2006090261 (2006).
- VERTEX PHARMACEUTICALS, INC.: WO200222610 (2002).
- F HOFFMANN-LA ROCHE AG: WO2003076429 (2003).
- MERCK PATENT GMBH: WO2004030672 (2004).
- MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH: US5227508B1 (1993).
- GEORGETOWN UNIVERSITY: US6245754B1 (2001).
- ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, AND GEORGETOWN UNIVERSITY: US6667340B1 (2003)
- GEORGETOWN UNIVERSITY: WO2004022569 (2004).
- SMITHKLINE BEECHAM CORP.: WO2005085227 (2005).
- SMITHKLINE BEECHAM CORP.: WO2005011700 (2005).
- SMITHKLINE BEECHAM CORP.: WO2005046678 (2005).